Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-321 + Depatuxizumab mafodotin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-321 | ABBV321|ABBV 321|Serclutamab talirine | EGFR Antibody 63 | ABBV-321 (serclutamab talirine) is an antibody-drug conjugate (ADC) consisting of a monoclonal EGFR antibody and the cytotoxic agent, pyrrolobenzodiazepine, which may lead to inhibition of tumor growth (PMID: 32847977). | |
Depatuxizumab mafodotin | ABT-414|depatux-m | EGFR Antibody 63 | Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to an anti-microtubule drug, which delivers the cytotoxic agent to EGFR-expressing cells, potentially resulting in increased tumor cell death and decreased growth of EGFR-overexpressing tumors (PMID: 26846818, PMID: 29075855, PMID: 31747009, PMID: 32371586). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|